Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis

A. Ravelli, S. Viola, B. Ramenghi, L. Aramini, N. Ruperto, A. Martini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective. To investigate the outcome of children with juvenile rheumatoid arthritis (JRA) who discontinued taking methotrexate (MTX) therapy after the achievement of clinical remission. Methods. We conducted a retrospective review of the clinical course of all consecutive patients with JRA treated with MTX at our department. Results. Seventeen of the 30 patients who responded to treatment entered clinical remission 6 to 30 mo after beginning MTX therapy. All patients were discontinued from MTX within 2 to 5 mo. Five patients relapsed within 9 mo, whereas 12 patients had sustained remission for 12 mo or longer. Four of 5 children with extended pauciarticular JRA relapsed early after MTX discontinuation. These patients were less responsive to a further cycle of MTX, and 3 showed progression of radiographic joint lesions. Conclusion. These findings suggest that MTX should be continued in patients with extended pauciarticular JRA even after the achievement of clinical remission.

Original languageEnglish
Pages (from-to)1574-1576
Number of pages3
JournalJournal of Rheumatology
Volume22
Issue number8
Publication statusPublished - 1995

Fingerprint

Juvenile Arthritis
Methotrexate
Recurrence
Therapeutics
Joints

Keywords

  • Juvenile rheumatoid arthritis
  • Methotrexate

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. / Ravelli, A.; Viola, S.; Ramenghi, B.; Aramini, L.; Ruperto, N.; Martini, A.

In: Journal of Rheumatology, Vol. 22, No. 8, 1995, p. 1574-1576.

Research output: Contribution to journalArticle

@article{27b0ac2015ef4b9293358f4b5b82687c,
title = "Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis",
abstract = "Objective. To investigate the outcome of children with juvenile rheumatoid arthritis (JRA) who discontinued taking methotrexate (MTX) therapy after the achievement of clinical remission. Methods. We conducted a retrospective review of the clinical course of all consecutive patients with JRA treated with MTX at our department. Results. Seventeen of the 30 patients who responded to treatment entered clinical remission 6 to 30 mo after beginning MTX therapy. All patients were discontinued from MTX within 2 to 5 mo. Five patients relapsed within 9 mo, whereas 12 patients had sustained remission for 12 mo or longer. Four of 5 children with extended pauciarticular JRA relapsed early after MTX discontinuation. These patients were less responsive to a further cycle of MTX, and 3 showed progression of radiographic joint lesions. Conclusion. These findings suggest that MTX should be continued in patients with extended pauciarticular JRA even after the achievement of clinical remission.",
keywords = "Juvenile rheumatoid arthritis, Methotrexate",
author = "A. Ravelli and S. Viola and B. Ramenghi and L. Aramini and N. Ruperto and A. Martini",
year = "1995",
language = "English",
volume = "22",
pages = "1574--1576",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis

AU - Ravelli, A.

AU - Viola, S.

AU - Ramenghi, B.

AU - Aramini, L.

AU - Ruperto, N.

AU - Martini, A.

PY - 1995

Y1 - 1995

N2 - Objective. To investigate the outcome of children with juvenile rheumatoid arthritis (JRA) who discontinued taking methotrexate (MTX) therapy after the achievement of clinical remission. Methods. We conducted a retrospective review of the clinical course of all consecutive patients with JRA treated with MTX at our department. Results. Seventeen of the 30 patients who responded to treatment entered clinical remission 6 to 30 mo after beginning MTX therapy. All patients were discontinued from MTX within 2 to 5 mo. Five patients relapsed within 9 mo, whereas 12 patients had sustained remission for 12 mo or longer. Four of 5 children with extended pauciarticular JRA relapsed early after MTX discontinuation. These patients were less responsive to a further cycle of MTX, and 3 showed progression of radiographic joint lesions. Conclusion. These findings suggest that MTX should be continued in patients with extended pauciarticular JRA even after the achievement of clinical remission.

AB - Objective. To investigate the outcome of children with juvenile rheumatoid arthritis (JRA) who discontinued taking methotrexate (MTX) therapy after the achievement of clinical remission. Methods. We conducted a retrospective review of the clinical course of all consecutive patients with JRA treated with MTX at our department. Results. Seventeen of the 30 patients who responded to treatment entered clinical remission 6 to 30 mo after beginning MTX therapy. All patients were discontinued from MTX within 2 to 5 mo. Five patients relapsed within 9 mo, whereas 12 patients had sustained remission for 12 mo or longer. Four of 5 children with extended pauciarticular JRA relapsed early after MTX discontinuation. These patients were less responsive to a further cycle of MTX, and 3 showed progression of radiographic joint lesions. Conclusion. These findings suggest that MTX should be continued in patients with extended pauciarticular JRA even after the achievement of clinical remission.

KW - Juvenile rheumatoid arthritis

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0029148088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029148088&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 1574

EP - 1576

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -